Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients Before and After Treatment with First-Line Immunomodulatory Therapies
Serum neurofilament light chain (NfL) has been shown to correlate with neuroaxonal damage in multiple sclerosis (MS) and various other neurological diseases. While serum NfL is now regularly reported in clinical approval studies, there is a lack of longitudinal data from patients treated with establ...
Main Authors: | André Huss, Makbule Senel, Ahmed Abdelhak, Benjamin Mayer, Jan Kassubek, Albert C. Ludolph, Markus Otto, Hayrettin Tumani |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/8/9/312 |
Similar Items
-
A Score Based on NfL and Glial Markers May Differentiate Between Relapsing–Remitting and Progressive MS Course
by: André Huss, et al.
Published: (2020-07-01) -
Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?
by: Ahmed Abdelhak, et al.
Published: (2015-07-01) -
Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis
by: Dejan Jakimovski, et al.
Published: (2020-09-01) -
Diagnostic and Prognostic Performance of Neurofilaments in ALS
by: Koen Poesen, et al.
Published: (2019-01-01) -
Current application of neurofilaments in amyotrophic lateral sclerosis and future perspectives
by: Yuri Matteo Falzone, et al.
Published: (2021-01-01)